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Abstract
G protein-coupled receptors, whose topology shows seven transmembrane domains, form the largest known family of receptors involved
in higher organism signal transduction. These receptors are generally of low natural abundance and overexpression is usually a prerequisite to
their structural or functional characterisation. The baculovirus–insect cell system constitutes a versatile tool for the maximal production of
receptors. This heterologous expression system also provides interesting alternatives for receptor functional studies in a well-controlled
cellular context.
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1. Introduction
G protein-coupled receptors (GPCRs) form the fourth
largest superfamily in the human genome with more than
600 genes identified to date [1]. They have in common a
topology based on seven-transmembrane a-helical domains
and coupling to heterotrimeric G proteins (Gahg). GPCRs
mediate the effect of numerous ligands including neuro-
transmitters, chemoattractants, hormones, cytokines and
sensory stimuli such as photons and odorants. Binding of
extracellular ligands initiates the signal transduction cascade
by triggering conformational changes in the receptor that
promote Ga subunit activation [2,3]. Following nucleotide
exchange (GDP replacement by GTP), the tightly associated
Ga and Ghg subunits separate from each other and from the
receptor. Both components are then free to interact and
modulate the activity of downstream elements of the signal-
ling cascades such as adenylyl cyclase or ion channels.
Signal transduction is tightly regulated by receptor phos-
phorylation and subsequent interaction with arrestins as well
as by the interplay of G-protein subunits with ‘‘regulators of
G-protein signalling’’ (RGS). Tremendous progress has
been accomplished within the last few years in dissecting
GPCR-mediated signal transduction pathways, but the
molecular mechanisms underlying ligand recognition and
signal transduction through the membrane are restrained by
the lack of detailed receptor structures. To date, only the 3D
structure of rhodopsin has been solved at high resolution
[4].
Structural characterisation of a protein may be achieved
using different biophysical and biochemical approaches that
often require several milligrams of protein per assay. The
low natural abundance of most GPCRs precludes the use of
such methods of investigation. For more than 10 years,
efforts have been made to overcome this problem, leading to
the use of heterologous organisms for protein production
[5–7].
Escherichia coli is an attractive expression system
because it is easy to scale-up and cheap to grow, but there
are some drawbacks associated with the prokaryotic nature
of the organism. For example, the low percentage of GC
nucleotides in the genome when compared to mammalian
genes or the existence of rare codons often result at least for
soluble proteins in low expression levels or truncated forms
[8,9]. Heterologous expression in bacteria also suffers from
the inability of prokaryotes to perform any post-translational
modifications (e.g. glycosylation, fatty acid acylation, phos-
phorylation) some of which are known to be of critical
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relevance for protein function. Also, the lack of G proteins
in bacteria affects the properties of the expressed GPCRs
though successful interaction with a Ga subunit in fusion
[10] or added to the membrane-bound receptor has been
demonstrated [11]. Therefore, E. coli is most often chosen to
provide material suitable for structural studies. In spite of
many efforts invested in the design of fusion proteins and/or
selection or engineering of bacterial strains, GPCR expres-
sion levels at the inner membrane are still often poor (most
often less than 200 receptors/cell) and receptor production is
often perceived as toxic by the cell. However, in the best
cases, up to 3500 copies per cell of functional muscarinic m1
receptor (0.66 mg/l culture) have been produced in E. coli,
allowing the purification of milligrams of receptor [12].
Folding of some heterologous membrane proteins may be
hindered by the lack of appropriate chaperones leading to
accumulation of misfolded proteins in the cytoplasm and
formation of the so-called inclusion bodies which requires
subsequent refolding of the protein [13,14].
Yeast is another small organism for which large-scale cul-
ture is easily achieved. Saccharomyces cerevisiae, Schizo-
saccharomyces pombe as well as the methylotrophic Pichia
pastoris have been used successfully for GPCR expression
[15]. Expression levels reported for GPCRs were generally
about 1–2 pmol/mg membrane proteins but serotonin
5-HT5A, h2- and a2-adrenergic as well as dopamine D2
receptors were produced at levels well exceeding 10 pmol/
mg membrane proteins [15]. Yeast cells offer a cellular
context able to perform post-translational modifications sim-
ilar to other more complex eukaryotic cells. However, N-
glycosylation of mammalian membrane proteins in yeast
seems to be very inefficient [5,6]. It is also worth noting that
the yeast cell is surrounded by a cell wall that may hinder
recovery of nonsecreted proteins.
GPCR expression in mammalian cells represents the
closest alternative to their native environment. Heterologous
protein production may be achieved through transient or
stable expression and various cell lines are available (e.g.
Cos, CHO, BHK 21, HEK 293, GH3). This system is
widely used for functional studies especially when post-
translational modifications such as N-glycosylation or pro-
teolytic processing are a prerequisite to function. Usually,
GPCR expression levels do not exceed 5–10 pmol/mg
membrane proteins but some host cell lines, for example,
HEK 293, are able to grow in suspension and are suitable
for large-scale biofermentors. However, very high expres-
sion levels of the h2-adrenergic or opioid receptors could
not be maintained in suspension culture [7,16]. Unfortu-
nately, scaling up of adherent cell cultures is a rather
arduous and costly process, so mammalian cells are not
altogether preferred for GPCR overproduction.
In this context, the baculovirus system offers a very
attractive alternative that has been widely taken advantage
of. It is, however, important to bear in mind that the right
combination between receptor and heterologous host has to
be found and that no universal system is likely applicable to
all GPCRs. When dealing with structural aspects, amounts
of protein produced are the limiting step while post-trans-
lational modifications as well as a cellular environment
close to the native one are essential when studying func-
tional aspects. Both criteria can rarely be fulfilled by one
single heterologous expression system. Depending on the
final goal, one system may prove more adapted than another
and expression may be performed in several heterologous
systems simultaneously to address different questions.
2. What is the baculovirus system?
In the eukaryotic expression system based on the use of
baculovirus, protein production results from infection of
insect cells by recombinant viruses encoding the gene(s) to
be expressed. The cDNA of interest is inserted into a plasmid
transfer vector that is introduced by homologous recombi-
nation into the genome of a baculovirus, usually Autographa
californica multiply embedded nuclear polyhedrosis virus
(AcMNPV). In most cases, the very strong polyhedrin
promoter drives expression. Polyhedrin is naturally produced
at very high levels (up to 20% of the total protein synthe-
sised) and is nonessential for viral propagation in cell culture,
and it can therefore be replaced by any gene of interest. Other
promoters can also be used such as the p10 promoter. Both
the polyhedrin and p10 promoters are ‘very late’ promoters
because they are only switched on about 24 h post viral
infection (Fig. 1). Both promoters drive the expression of
two major components of occlusion bodies that are located
within the nucleus and can be described to form a proteina-
ceous matrix in which viral particles are embedded and
protected from the external environment. Several copies of
the polyhedrin and p10 promoters can also be used simulta-
neously when two or more proteins are to be expressed [17].
The system is therefore suitable for production of multimeric
proteins [18,19] or for the reconstitution of partnerships such
as those taking place in the early steps of the signalling
cascade (see below). Expression of heterologous proteins
under the control of the very late promoters peaks usually
48–72 h post infection. The viral cycle is lytic and causes
cell death about 4–5 days post infection; there is, therefore,
considerable interest in promoters that would start protein
production earlier, allowing more time for post-translational
modifications to take place. The basic protein promoter
drives the production of a small protein involved in DNA
compaction as early as 6–8 h post viral infection. It has been
successfully used for heterologous protein production
including GPCRs, but maximal expression levels were
markedly lower than those reached under the control of the
polyhedrin promoter (Ref. [20], Massotte unpublished data).
Therefore, this promoter is not much favoured for over-
expression.
Since its first description for heterologous protein expres-
sion almost 20 years ago [21], the baculovirus system has
inherited many technical improvements along the years to
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become a relatively simple technique that can be readily
introduced into most laboratories [22,23]. Protocols are well
established and most of the tools for recombinant virus
generation as well as cell culture and protein production are
commercially available. The narrow host cell range
restricted mainly to insects makes baculoviruses attractive
because they do not require extensive biosafety measures.
Indeed, baculoviruses can infect various mammalian cells
including hepatocytes, but they show no evidence of repli-
cation in such cells [24,25].
Insect cells are semi-adherent, they grow easily in
suspension and they can be adapted to serum-free media
allowing easy scale-up in large biofermentors. Insect cells
are also able to perform post-translational modifications
identical to those of mammalian cells (e.g. phosphorylation,
fatty acid acylation, glycosylation) and recombinant pro-
teins exhibit characteristics very similar if not identical to
their native counterparts. It is worth mentioning that N-
glycosylation is often more simple than in mammalian cells
and remains of the high-mannose type [26]. Cells derived
from Spodoptera frugiperda ovarian tissue (Sf9 and Sf21)
are the most widely used but attempts have been made to
broaden the number of available cellular lines to improve
protein production [Trichoplusia ni (High Fivek)] [27–29]
or to produce glycosylation patterns of the complex and
hybrid types in cell lines derived from T. ni and Estigmena
acrea, respectively [30,31].
3. GPCR overexpression for structural studies
Structural studies require fairly large amounts of protein,
often exceeding milligram quantities, of a receptor in a fully
functional state. Heterologous expression with the baculo-
virus–insect cell system ensures production of good protein
quantities in cells performing post-translational modifica-
tions essentially identical to those occurring in naturally
producing tissues. This guarantees high-level expression of
recombinant GPCRs with characteristics almost identical to
their native counterparts, making them ideal for subsequent
structural studies.
3.1. GPCR maximal levels of expression
Baculovirus-infected insect cells have proven very effi-
cient for membrane protein production and have achieved
successful overexpression of numerous GPCRs such as
several dopamine, serotonin, muscarinic, opioid or adrener-
gic subtypes. As reviewed by Grisshammer and Tate [5] in
1995, amounts of receptors produced were generally in the
range of 5–30 pmol/mg protein and 1–2 106 receptor
sites were generally present per cell. These amounts are 25–
600 times higher than those obtained in the naturally
producing mammalian cells. Since Grisshammer and Tate’s
comprehensive review, some yields of expression have been
improved and other receptor types successfully expressed.
In several cases, receptor production exceeded well 30
pmol/mg protein (Table 1).
3.2. Development of tools to improve GPCR expression and
purification
Several attempts have been made to improve GPCR
expression with the baculovirus system. Membrane pro-
teins, like secreted soluble polypeptides, travel through the
cell secretory pathway to reach the cell outer membrane.
Fig. 1. Time-scale of baculovirus infection showing the three successive phases of infection. Vertical arrows point out the main events taking place respectively
in the early, late and very late phases. Promoters used for GPCR expression are indicated within parentheses. An approximate time-scale for the main events is
also mentioned.
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Hence, solutions brought to address secretion or folding
problems of secreted proteins are often of use for mem-
brane polypeptides. Fusions to a variety of signal sequen-
ces from baculoviral, prokaryotic or eukaryotic origin
successfully increased the amount of soluble secreted
proteins [32–35]; the N terminus of all GPCRs is pre-
dicted to be on the extracellular surface of the plasma
membrane, so attempts were therefore made to use a
similar strategy to increase GPCR production. In contrast
to other protein families, most GPCRs are not synthesised
as a pro-receptor with an N-terminal signal sequence
preceding the mature protein coding sequence. In fact,
addition of a cleavable signal sequence ahead of the GPCR
coding sequence improved expression levels (Table 1)
whether derived from the Apis melifera melittin in the
case of the human dopamine D2S receptor [27] or the
influenza hemagglutinin in the case of the human h2-
adrenergic receptor [36]. The signal sequence of the
baculoviral gp64, a glycoprotein involved in membrane
fusion, also led to high expression levels of the human mu
opioid [29], the 5-HT1B and 5-HT1D [37] or 5-HT5D [38]
receptors.
Crude cell membrane extracts from baculovirus-infected
cells contain immature GPCRs probably representing a
fraction of proteins trapped in the membranes of endoplas-
mic reticulum (ER) and Golgi apparatus as a result of the
biosynthetic pathway saturation. A step based on the bio-
logical activity of the receptor such as a ligand affinity
column was often included in purification schemes to
eliminate nonfunctional misfolded receptors [39–41]. Engi-
neering of the insect cells could also be undertaken to try
and prevent the formation of misfolded receptor and there-
fore optimise GPCR expression. As already mentioned,
secreted and membrane proteins share in common the
requirement of moving along the secretory pathway to be
respectively released in the extracellular environment or
routed to the plasma membrane, explaining why addressing
secretion or folding problems of secreted proteins may result
in improvements in membrane protein production. Co-
expression of chaperones such as the ER-resident BiP
(immunoglobin heavy chain binding protein), calreticulin
or the ER membrane-bound calnexin appeared an attractive
strategy (reviewed in Ref. [42]) that could be applied to the
GPCR family. Calnexin associates with a number of mem-
Table 1
GPCRs expressed for the first time or for which expression was improved since 1995
Receptor Type Origin Signal sequence Maximal expression level Reference
Adenosine A2A Human 19F 4 pmol/mg [50]
26F 4 pmol/mg [135]
Adenosine A2A Human N-(his)6-flag 48F 5 pmol/mg [50]
Bradykinin B2 Human 2 pmol/mg [146]
2.57 pmol/mg [77]
Cannabinoid CB1 Human 15 pmol/mg [144]
Cannabinoid CB2 Human 33 pmol/mg [144]
Dopamine D2S Human mellitin 6–10 pmol/mg [27]
Dopamine D2S Rat 5–8 pmol/mg [109]
Dopamine D2L Rat 5–8 pmol/mg [109]
Dopamine D3 Human 10–12 pmol/mg [153]
Endothelin B Human 100 pmol/mg [49]
Gonadotropin-releasing
hormone
Rat 7800F 650 receptors/cell
= 10 fmol/mg
[154]
Histamine H2 Rat 6.6F 0.6 pmol/mg [102]
Hydroxytryptamine 5-HT1A Human 5–22 pmol/mg [60]
Hydroxytryptamine 5-HT1B Human gp64 22F 1.5
a pmol/mg [37]
Hydroxytryptamine 5-HT1D Human gp64 31.6F 1.8 pmol/mg or
21.8F 6.1a pmol/mg
[37]
Hydroxytryptamine 5-HT2C Rat 50–70 pmol/mg [145]
Hydroxytryptamine 5-HT5A Human none 23F 2 pmol/mg [38]
Hydroxytryptamine gp64 63F 11 pmol/mg [38]
Kinin B1 Human 150 fmol/mg [146]
Luteinizing hormone Mouse 0.8 pmol/mg [20]
Opioid delta Human 85000–110000 receptors/cellb [48]
Opioid kappa Human 30000–50000 receptors/cellb [48]
Opioid mu Human none 400000–500000 receptors/cellb [48]
Opioid gp64 2.7 106–5.4 106 receptors/cell
= 12–25 pmol/mg
[29]
PACAP Human 82.6F 3.8 pmol/mg [40]
Substance P Human 65 pmol/mg [155]
Thrombin Human 0.78 mg/l = 16 nmol/l [156]
For older references, see Ref. [5].
a Measured with an agonist.
b As a rough estimate for conversion of expression levels, 106 receptors/cell is about 10 pmol/mg membrane proteins (for a 45-kDa protein) [5].
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brane or secreted glycoprotein intermediates and prevents
them from entering unproductive folding pathways [43]. It
has successfully increased expression of the serotonin trans-
porter by almost 200% [44] and expression of the human
taurine transporter fused to glutathione S-transferase by 54%
[45]. Catalytic enzymes, on the other hand, accelerate
folding along the proper pathway. Their use for membrane
proteins was shown in the case of the human dopamine
transporter, the expression of which was increased in an
insect cell line stably transformed with the peptidyl-prolyl
cis– trans isomerase that catalyses the cis– trans isomer-
isation of an X-Pro bond [46].
Influence of the culture medium on maximal receptor
expression has also been reported. In culture conditions in
which Sf9 cells had been adapted to serum-free medium, the
human mu opioid receptor fused to the gp64 signal
sequence was expressed about twice as much as in Sf9
cells grown in the presence of serum and at levels com-
parable to those obtained in T. ni cells adapted to serum-free
medium [29]. This latter observation suggests that higher
expression levels observed in T. ni cells compared to Sf9 are
due to serum-free culture conditions rather than to a cell line
effect [29]. High levels of expression (20 nmol/l) were also
obtained for the human h2-adrenergic receptor fused to the
hemagglutinin signal sequence and a C-terminal (His)6 tag
in Sf9 cells adapted to serum-free medium [39] and pro-
duction of bovine rhodopsin was increased up to double in
Sf9 cells adapted to serum-free medium [47]. Interestingly,
opioid receptor expression peaked earlier after viral infec-
tion in cells adapted in serum-free medium (Sf9 or T. ni)
when compared to expression in the presence of serum,
suggesting that serum depletion exerts a direct influence on
the cell metabolism and hence protein production [29].
Efforts have also been made to facilitate downstream
purification of the receptors. A hexahistidine (His)6 tag has
often been added to the protein which allows the use of an
affinity step on an ion chelating resin for an efficient
purification step. A systematic study using human opioid
receptors examined the influence of this tag on the receptor
production. The authors showed that addition of a (His)6 tag
did not interfere with ligand binding whether located at the
N or C terminus of the receptor [29,48]. However, (His)6
addition at the N terminus reduced drastically the expression
levels of delta, kappa and mu opioid receptors, whereas
(His)6 addition at the C terminus proved to be less delete-
rious. In fact, (His)6 addition at the C terminus reduced
expression only 2-fold in Sf9 and T. ni cells, but (His)6
addition at the N terminus decreased the expression level at
least 6- to 8-fold in Sf9 cells and 20-fold in T. ni cells
[29,48]. Addition of a (His)6 tag at the C terminus of the
human dopamine D2s receptor also had a negative influence
on the receptor processing as revealed by a reduced amount
of glycosylated receptor [27]. On the other hand, no
decrease in the level of expression was reported for the
endothelin B receptor following addition of a (His)6 tag at
its C terminus [49] and addition of a (His)6-Flag tag at the N
terminus of the human adenosine A2a receptor increased two
to three times expression levels when compared to the
native sequence [50]. As outlined by those examples,
prediction of expression levels after the addition of a tag
is very difficult because the way a sequence alters the
expression level appears to be rather receptor specific.
Noteworthy novel strategies are still explored with the
hope to improve the current state of art. In such an attempt,
the h2-adrenergic [51] as well as the muscarinic m1 and
dopamine D1 [52] receptors could be recovered from extra-
cellular baculovirus particles. This is a consequence of the
budding process during which the viral particles released
from the cell acquire an envelope or ‘‘loosely fitting’’ lipid
bilayer derived from the cell plasma membrane. Only mature
fully processed receptors were identified in extracellular
baculovirus particles. Also, those receptors were coupled
to the adenylyl cyclase as demonstrated by its stimulation
following agonist treatment. This approach may therefore
offer an easy alternative for producing homogenous popula-
tions of functional GPCRs although the amounts produced
per litre of culture are relatively low.
3.3. Large-scale production in biofermentors
The amounts of GPCR produced per cell and litre of
culture with the baculovirus system represent a great
improvement compared to natural expression yields (up to
several hundred-fold increase), but structural studies are
very demanding and large-scale cultures have to be envis-
aged. Insect cells are semi-adherent, allowing both growth
under attached conditions (rollers, micro-carriers) or in
suspension (shakers, airlift, or stirred tank). However, the
cells are also very sensitive to shear damage resulting from
gas bubbling. This can be reduced by different additives
such as Pluronic F-68, a tensioactive compound that pre-
vents the cells from attaching to the gas–medium interface
[53]. Biofermentors allow not only large culture volumes
but also control of optimised conditions for protein produc-
tion. Oxygen proves to be a crucial rate-limiting component
because its consumption increases drastically following
viral infection. Volumes of 60 l or more are used in industry
but, at the laboratory scale, biofermentors are rarely larger
than 5–10 l. Over the years, numerous protocols for culture
and infection in spinner flasks or biofermentors have been
established [54–58].
One drawback of the baculovirus system is the require-
ment for high-titre viral stocks to infect cultures. The
systematic study performed on opioid receptor production
showed that the optimal multiplicity of infection for most
constructs tested was lower in Sf9 cells compared to T. ni
cells [29]. This is of importance if one considers the buildup
of large viral stocks. Because the virus is lytic, attention has
also to be paid when deciding for optimal multiplicity of
infection and very often the use of a semicontinuous system
or repeated batches was preferred over continuous produc-
tion. Also, culture in a continuous reactor is limited to a
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maximum of 30 days. For longer times, an inevitable loss of
production happens, probably due to a high proportion of
defective viral particles [59].
Despite the variety of biofermentor designs that have
been studied and used in academic work and industry, no
single system has proven to be universally superior in
productivity and easiness of scale-up. Both attached and
suspension growth systems present advantages though the
latter is often favoured because of its simplicity and the
long-standing experience from microbial fermentation.
3.4. Post-translational modifications
Among post-translational modifications, palmitoylation
plays a major role in the regulation of GPCR function. This
reversible fatty acid acylation corresponds to the covalent
attachment of palmitic acid to cysteine residues via a
hydroxylamine-labile thioester bond and it is often very
difficult to study due to the low natural abundance of the
receptors. Heterologous expression using mammalian cell
lines such as CHO or HEK 293 partially alleviated this
problem. Nevertheless, some GPCRs are still too poorly
expressed in those cells. Indeed, the low specific activity of
[3H] or [14C] palmitate used in metabolic experiments
makes it extremely difficult to detect palmitoylation of
GPCRs expressed in mammalian cells. Therefore, over-
expression in insect cells with the baculovirus system
proved to be very helpful because insect cells perform
post-translational modifications identical to mammalian
ones with the exception of glycosylation (see below).
Palmitoylation of the human dopamine D2s [27], human 5-
HT1A [60], human 5-HT1B [61], GluR6 kainate [62], murine
5-HT4(a) [63] and human mu opioid (Massotte, unpublished
data) receptors have been established using the baculovirus
expression system. Palmitoylation is a dynamic process [64]
and the high level of receptor expression also allowed the
determination of its kinetics as well as increased turnover
upon agonist stimulation [65,66]. Recent studies in mam-
malian cells have confirmed the biological role of the
dynamic palmitoylation process which validates the use of
insect cells for those studies [67–71].
GPCR agonist-induced phosphorylation has been simi-
larly demonstrated in baculovirus-infected insect cells for
the human m2 [72] and m3 muscarinic [73], human 5-HT1B
[61] and 5-HT1A [74], dopamine D1 [75] and D2 [27],
substance P [76] and bradykinin B2 [77] receptors. Phos-
phorylation is critically involved in receptor desensitisation
and advantage has also been taken of its co-expression with
a given G protein-coupled receptor kinase (GRK) to get
better insights in this central regulatory mechanism (see
GPCR Overexpression for Functional Studies).
Most proteins present at the extracellular surface of
mammalian cells are glycosylated. Two main roles have
been postulated for the need of N-glycosylation. Inside the
cell, it helps proteins to fold and assemble correctly in the
ER where proteins like calnexin and calreticulin act as
chaperones that recognise and bind to the carbohydrate
portion of newly synthesised proteins. Misfolded glycopro-
teins are then selectively eliminated from the ER by a
stringent process of conformation-based quality control
[43]. Outside the cell, carbohydrates provide specific rec-
ognition structures for interaction with a variety of external
effectors intervening in processes such as the modulation of
neural plasticity [78]. Also, sialic acids are known to play an
important role in the in vivo clearance rate of proteins [31].
The functional role(s) of glycosylation in the case of most
GPCRs is still unclear, but it has been shown that many
GPCRs do not depend on the presence of N-glycans for
ligand recognition [79–81]. One interesting case is the
human mu opioid receptor where a single nucleotide poly-
morphism has been identified resulting in the replacement of
asparagine 40, a putative site for N-glycosylation, by an
aspartate residue [82]. This mutation appeared rather fre-
quently in different clinical studies aiming at identifying
polymorphisms associated with addictive disorders and it
has been suggested that the absence of glycosylation may
influence the physiological responses to drug intake.
Glycosylation in insect cells remains mostly very simple
of the high mannose type. The inability of insect cells to
perform complex glycosylation is apparently due to the
absence or insufficient amounts of the terminal glycosyl-
transferases that are required to convert N-linked side chains
to complex forms [83]. Metabolic engineering can be used
to extend the glycoprotein processing capability of insect
cells and to express heterologous glycoproteins with glycans
that more closely resemble those produced by higher euka-
ryotes. The paradigm is based on the incorporation of
mammalian glycosyltransferases into the insect cell by
stable transformation of the cells that now express the
enzymes mainly under the control of baculoviral immedi-
ate-early promoters (Refs. [83,84] and references therein).
Another approach focused on the search for insect cell lines
that contain endogenous enzymes able to perform a more
complete sugar triggering such as E. acrea [30]. Strict
control of growth and infection parameters, especially dis-
solved oxygen, was also used to improve glycosylation by
endogenous enzymes [85].
Upon GPCR overexpression with the baculovirus sys-
tem, a large portion of the recombinant protein is often not
glycosylated at all as a likely consequence of the saturation
of the cell machinery. Overall glycosylation is thought to
influence protein stability, folding and solubility and, hence,
receptor expression levels (Ref. [86] and references therein),
but ligand binding and signalling properties were, in most
cases, identical to those of the naturally produced receptors
[27,40,48,86,87]. Heterogeneity in glycosylation may affect
3D crystallisation attempts, but glycosylated proteins can be
easily separated from unglycosylated ones on lectin affinity
columns [88]. Though it is generally admitted that glyco-
sylation introduces perturbations and flexibility that are
undesirable during crystallogenesis [89], several soluble
glycoproteins have been crystallised (e.g. Refs. [90–92])
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as well as the GPCR rhodopsin [4] and, in two cases at least,
sugars were crucial for crystal lattice formation by forming
bridges between adjacent proteins [93,94].
3.5. Influence of membrane lipid composition
Compared to mammalian cells, the Sf9 cell plasma
membrane contains higher amounts of unsaturated lipids
and lower amounts of cholesterol to ensure membrane
fluidity at the organism growth temperature (27–28 jC)
[95]. Moreover, baculovirus infection changes the lipid
composition of the membrane through enrichment in phos-
phatidylcholine [95]. Several reports have pointed out the
influence of membrane lipid composition on GPCR activity,
showing that acyl chain saturation [96], negatively charged
lipids [97] and/or cholesterol [98–100] constitute parame-
ters that sometimes influence receptor functionality. For
example, the human oxytocin [101] and the histamine H2
[102] receptors were expressed in a low-affinity state in Sf9
cells; addition of cholesterol by incubation of the cells with
cholesterol-h-cyclodextrin complexes led to an increased
amount of high-affinity binding sites. Thus, in some cases,
overexpression increases the amount of receptors produced
in a nonactive conformation by reducing the overall avail-
ability of less abundant membrane components.
4. GPCR overexpression for functional studies
Functional as well as structural studies require character-
istics of the recombinant protein indistinguishable from the
native one. It should also be kept in mind that the func-
tional activity of a GPCR is strongly dependent upon cell
type and receptor density: for instance, the presence and
relative concentrations of signal transduction elements may
drastically affect ligand and G-protein binding properties
[103,104]. All these parameters ought to be taken into
account when addressing pharmacological properties such
as ligand affinities or when depicting the nature of, and
interrelations between, signal transduction components. The
baculovirus expression system has proven to be very
successful in studying the intrinsic properties of receptors
and their G protein-coupling specificity.
4.1. Endogenous Ga subunit composition
The G proteins Gsa and Gqa have been unambiguously
identified in Sf9 cells [20,105,106], but some debate
remains concerning the presence of Gi/oa subunits. Several
laboratories were unable to detect Gi/oa subunits with
antibodies raised against their mammalian counterparts
[20,105–107]. On the other hand, a partial cDNA encod-
ing a Go-likea was isolated from insect cells [61] and Goa,
but not Gia, could be detected by immunoblotting [108].
The presence of a Go-likea was further supported by the
recovery of high-affinity agonist binding sites for the 5-
HT1A receptor when it was expressed at a level compara-
ble to naturally occurring ones (150 fmol/mg membrane
protein) [108]. Similarly, dopamine D2 coupling to endog-
enous Gi/oa proteins could be detected if the receptor was
expressed at levels below 1 pmol/mg membrane protein
with no more than 40 fmol/mg membrane protein high-
affinity binding sites [109]. Therefore, the absence of
coupling to endogenous G proteins reported by other labo-
ratories may result from the high expression levels of receptor
that were achieved (>27 pmol/mg proteins) [106,107]. Inter-
estingly, Leopoldt et al. [110] detected Gi/oa subunits in
uninfected Sf9 cells, but reported endogenous Ga protein
down-regulation on prolonged baculovirus infection as
shown by (1) decreased [35S]-GTPgS incorporation, (2)
pertussis toxin (PTX)-mediated [32P]-ADP ribosylation, (3)
G protein immunoreactivity, (4) [a32P]-GTP-azidoanilide
photolabelling of Ga and (5) [32P]-GTP labelling of Gh.
As an example, PTX-mediated [32P]-ADP ribosylation was
weak 62 h post infection and virtually undetectable 75 h
post infection. In addition, coupling to endogenous G
proteins by the histamine H1 and H2 receptors was
detected 28 h post infection, but no coupling was found
at 48 h post infection [110]. Down-regulation of endoge-
nous G proteins following baculovirus infection, as well as
different selectivity and/or sensitivity of the antibodies
used for endogenous G protein detection and identification,
are two factors that might reconcile the apparent contra-
dictions in Gi/oa content and receptor coupling states
reported by the various authors.
Post-translational modifications of heterotrimeric G pro-
teins have been extensively studied in Sf9 cells with no
differences being observed when compared to mammalian
cells. For example, Ga subunits are palmitoylated, which
is essential for interaction with the receptor [111–113], and
Gi/oa subtypes are myristoylated [114]. Similarly, post-
translational prenylation and carboxylmethylation of the
Gg subunit take place following hg dimer formation.
These latter modifications are essential for GaGhg,
Ghg-receptor and Ghg-effector interactions [115].
4.2. Overexpression as a tool for ligand screening
The high expression levels achieved in baculovirus-
infected insect cells result in amounts of receptors that
allow easy characterisation of their pharmacological pro-
files, which in turn identifies those receptors as a good
support for drug screening and development. It is now well
established that antagonist binding properties of the recep-
tors expressed in insect cells are identical to those
observed for receptors obtained from naturally producing
sources. In many examples, however, only the guanidine
nucleotide insensitive low-affinity state for agonist could
be detected [40,48,107,116]. This most likely reflects the
fact that the number of receptors expressed with the
baculovirus system exceeds enormously the number of
endogenous G proteins with which they can interact. It
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follows that only a tiny amount of the receptors are in the
high-affinity binding state for agonist that corresponds to
receptors interacting with heterotrimeric G proteins. In
such a situation, antagonists as well as inverse agonists
will bind to those uncoupled receptors, but agonist binding
will be limited. In many cases, the receptor has been
expressed together with its cognate Ga partners to ensure
that the G proteins are no longer limiting; this allows
complete characterisation of all types of ligands, including
agonists (see below).
4.3. Identification of interacting G protein partners
The baculovirus–insect cell system represents an excel-
lent choice for studying interactions of a given receptor with
its cognate G protein partners. Because well-defined recep-
tor–heterotrimeric G protein combinations can be produced,
unambiguous identification and characterisation of specific
interactions can be performed. By providing low endoge-
nous background and controlled expression of the effectors,
the system allows differentiation between the effects of
agonists, receptor subtypes, Ga subunits and/or Ghg com-
binations. The fact that specific receptor subtypes can be
expressed in a defined cell type allows the unambiguous
assignment of ligand selectivity which would be impossible
from naturally expressing tissues in which several receptor
subtypes co-localise, for example, the muscarinic subtypes
m1–m5 [117–119]. This may be of special interest if a
given receptor subtype is involved in a pathology, such as
those belonging to the 5-HT receptor family, and one wishes
to modulate its activity without affecting the other subtypes
[120].
Examples of identification and characterisation of
GPCR–heterotrimeric G protein partnerships are given in
Table 2. Four different experimental paradigms were used to
collect information. Each approach offers advantages and
drawbacks regarding its ability to mimic the receptor–G
protein ratio present in the native cellular environment.
4.3.1. Co-expression of the GPCR and G proteins
In this approach, no direct control can be exerted on the
ratio between the different effectors. The amount of the
different partners present within a given cell is variable and
depends on the number of different recombinant baculovi-
ruses that have co-infected the cell. Ghg subunits are
sometimes encoded on a single recombinant baculovirus
in an attempt to enhance co-infection efficiencies [17].
Whether expression levels of receptor and G protein influ-
ence each other reciprocally [121,122] or not [20] is still an
open question.
Studies of the interactions between the co-expressed
partners can be performed using membrane- or whole-cell-
based experiments. When using membranes, differences in
coupling between closely related receptors such as dopamine
D2L and D2S receptors were revealed as attested by the
increased affinity of D2S for Gi1ah1g2 compared to D2L
and differential cAMP inhibition [109]. Examples of func-
tional studies performed using intact cells include the dem-
onstration of the preferred coupling of the human dopamine
D2s receptor for Gi1a over Gi2a as assessed by GTPgS
binding, GTPase activity and the measurement of intracel-
lular cAMP on intact cells [121]. Electrophysiology has also
been a valuable tool to monitor agonist-evoked intracellular
responses. For example, the activation of potassium channels
upon addition of acetylcholine in Sf9 cells expressing the
muscarinic m3 receptor was shown by whole-cell current
recordings and patch-clamp techniques [123]. In another
study, 5-HT1A or 5-HT4(a) receptors were co-expressed in
baculovirus-infected Sf9 cells together with a cyclic nucleo-
tide-sensitive and voltage-activated cation channel from the
moth Heliothis virescens and either Giah1g2 or Gsah1g2
proteins, respectively. Hyperpolarization-activated inward
currents were measured in the whole-cell patch-clamp con-
figuration, which allowed the variation in the intracellular
cAMP concentration in response to receptor activation by
serotonin to be determined [71,124]. Fluorescent Ca2 +-sen-
sitive compounds have also been used to probe small varia-
tions in intracellular Ca2 + concentration caused by agonist-
induced stimulation of GPCRs. For example, the regulation
of the human bradykinin B2 receptor in Sf21 cells has been
observed in cells loaded with Fura-2-AM to monitor intra-
cellular Ca2 + mobilisation [77] while loading of Sf9 cells
with Fura-2 allowed detection of the increase in free Ca2 +
induced by endothelin receptors [125]. Recently, however,
limitations in the usefulness of Sf9 cells for the analysis of
receptor/Gqa coupling and Gqa-mediated activation of effec-
tors have been raised [126].
4.3.2. Expression of receptor–Ga fusion proteins
Receptor–Ga fusions allow a 1:1 ratio between the
partners as a result of their forced interaction. Because each
GPCR molecule is expressed together with the Ga subunit
of interest, it alleviates problems related to Ga availability.
This approach was successfully used for ligand screening
[127]. The imposed 1:1 coupling stoichiometry also shed
light on the mechanistic insights of G protein activation and
has been mainly used to study the h2-adrenergic receptor
signalling properties [128–132].
4.3.3. Addition of purified G proteins to membrane-bound
receptors
The main advantage of this method over the co-expres-
sion protocol resides in better control of the amounts of the
different partners interacting, because receptor and purified
G protein subunits can be separately quantified and mixed at
defined ratios. This paradigm was often chosen to examine
the role of Ghg in cell signalling [133]. It revealed the
impact of Ghg composition on receptor–Ga coupling and,
hence, on the choice of a signalling pathway. Examples
include the demonstration that the nature of Gh influences
directly receptor/Gsa coupling [134,135] and that Gg1 only
is able to promote rhodopsin/Gta interaction [136].
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4.3.4. Reconstitution in lipid vesicles of partners expressed
with the baculovirus system
This methodology takes advantage of the ability to
express and purify large amounts of GPCRs and heterotri-
meric G proteins and to introduce them into a fully artificial
environment where all parameters can be controlled. Cou-
pling of the h-adrenergic receptor to Gsa but not Gi/oa was
observed using this system, while the muscarinic m2 recep-
tor did not couple to Gsa but mainly to Goa and Gza and to
a much lesser extent to Gi1a or Gi3a [137]. Similarly,
reconstitution of the purified human PACAP receptor into
lipid vesicles with Gsa and Ghg led to GTPgS incorpo-
ration into Gsa and the appearance of high-affinity binding
sites [40].
4.4. Constitutive activity and inverse agonism
Constitutive activity reflects the spontaneous activity of
a receptor in the absence of agonist. This concept has
become widely accepted and verified for numerous GPCRs
Table 2
Determination of coupling specificity in baculovirus-infected Sf9 cells between defined GPCR subtypes, Ga and Ghg subunits
Receptor Type Origin Identified interacting
Ga proteins
Identified non-interacting
Ga proteins
Ghg subunits Reference
Adenosinea A2a Human Gs, h4g2>h2g2 =h3g2>h1g2 h5g2 [134]
Adenosineb A2a Human Gsh4g2 Gsh1g2 [135]
Adrenergicc h Turkey Gs Bovine brain [137]
Adrenergicb h1 Rat Gs Gz, Gq, G12, G13 h1g2 [157]
Adrenergica h1 Rat Gs, h1g2 =h3g2 =h4g2>h2g2 h5g2 [134]
Adrenergicb a2B Human Gs, Gi [158]
Cannabinoida CB1 Human Gi>Go Bovine brain [144]
Cannabinoida CB2 Human Gi{Go Bovine brain [144]
Dopamineb D2L Rat Go>Gi2 (agonist dependent) h1g2 [159]
Dopamineb D2S Human Gi1>Gi2 h1g2 [121]
Endothelina B Human Gqh1g2, Gqh5g2, Gi1h1g2 Gi1h5g2 [133]
Formyl peptided Human Gi1 =Gi2 =Gi3 h1g2 [160]
Histaminee H1 Guinea pig Gq/11 Endogenous Ghg [20]
Histaminee H1 Guinea pig Gq/11 Gi, G12 Endogenous Ghg [110]
Histaminee H2 Rat Gq/11, Gs Gi, G12 Endogenous Ghg [110]
Histaminee H2 Human Gs{Gq [126]
Histamineb,d H2 Human Gs mammalian Gq mammalian [126]
Hydroxytryptaminee 5-HT1A Human Go Endogenous Ghg [108]
Hydroxytryptamineb 5-HT1A Human Gi1 =Gi2 =Gi3 =Go =Gz Gs, Gq h1g2 =h1g3 =h1g5 <h1g1 [60]
Hydroxytryptamineb 5-HT1A Human Gz Gs, G12, G13, Gq h1g2 [157]
Hydroxytryptaminea 5-HT1A, 1B Human Gi3>Gi1, Gi2, Go Gt Bovine brain purified
or Gg retina
[161]
Hydroxytryptaminea 5-HT1D Human Gi3>Gi1, Gi2, Go Gt
Hydroxytryptaminea 5-HT1E Human Gt, Gi1, Gi2, Gi3, Go
Hydroxytryptamineb 5-HT1D Human Gi1, Gi2, Gi3, Go Gq h1g2 [37]
Hydroxytryptamineb 5-HT4(a) Murine G13, Gs Gi2, G12, Gq h1g2 [162]
Hydroxytryptamineb 5-HT5A Human Gi1, Gi2, Gi3, Go Gz, Gs, Gq, G11, G12,
G13, G16
h1g2 [38]
Luteinizing hormonee Mouse Gs (cAMP) Endogenous Ghg [20]
Luteinizing hormoneb Mouse Gi2>Gi3, Gs (PLC) Gi1, Gq, G11 h1g1, h2g2 [20]
Lysophosphatidic acidb Edg2-Vzg1 Mouse Gi1, GoA, G11 Gs h1g2 [122]
Muscarinica m1 Human Gqh1g2, Gqh5g2 [133]
Muscarinicc m2 Human Go, Gz>Gi1, Gi3 Gs Bovine brain [137]
Opioidb mu Human Gi1 Gi2 h1g2 [163]
Opioidb kappa Rat Gi1, GoA h1g2 [17]
PACAPc Human Gs Bovine brain [40]
Sphingosine1-phosphateb Edg-1 Human Gi1, Gi2, Gi3, Go1, Gz Gs, Gq, G12, G13 h1g2 [164]
Sphingosine1-phosphateb Edg-3 Human Gi2, Gq, G13 h1g2 [164]
Sphingosine1-phosphateb Edg-5 Rat Gi2, Gq, G13 h1g2 [164]
Substance Pe Human Go, Gq/11, Gs Endogenous Ghg [155]
Substance Pb NK1 Human Gq, G12, G13>Gz Gs h1g2 [157]
Thrombinb Human Gq, G12, G13>Gz Gs h1g2 [157,162]
a Addition of purified Ga to membranes expressing the receptor.
b Co-expression.
c Reconstitution of purified partners in lipid vesicles.
d GPCR–Ga fusion.
e Coupling to endogenous Ga.
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[37,138–140], and this ligand-independent activity is also
acknowledged to play a role in some pathologies [141].
Such constitutive activity is usually very difficult to detect
in naturally producing cells because of the very low level
of expression (fmol/mg membrane proteins) and heterolo-
gous expression in mammalian cells is not completely
satisfactory to solve the problem because expression levels
are often too low for optimal detection (generally 1–2
pmol/mg membrane protein). In contrast, the high expres-
sion levels of uncoupled receptors produced in insect cells
with the baculovirus system results in a good basal signal
[142–144]. Moreover, overexpression of the receptor
together with its cognate Ga partner resulted in amplifica-
tion of the signal arising from their spontaneous interaction
enabling easy demonstration of the receptor constitutive
activity (see below). Hence, this system also facilitated
drug screening for identification and characterisation of
compounds that reduce this basal activity, that is, inverse
agonists.
Spontaneous activation of the Ga subunit by the receptor
has been shown by co-expression of the GPCR and G
protein; for example, the 5-HT1A receptor and Gza [142],
the 5-HT1D receptor and Gi1a [37], the 5-HT2C receptor and
Gqa [145], the cannabinoid CB1 receptor and Gia [144], the
lysophosphatidic acid Edg2-Vzg1 receptor and Gi1a [122]
and the h2-adrenergic receptor and Gsa [143].There are also
examples where basal activity was shown by the expression
of a fusion protein between the receptor and the Ga subunit;
for example, the histamine H2 receptor fused to the long or
the short variants of Gsa [132] or the h2-adrenergic receptor
fused to the long splice variant of Gsa [128].
4.5. Regulation of GPCR activity
Because of the high level of receptor expressed with
the baculovirus system and the possibility to isolate one
particular receptor subtype, studies have been performed
on aspects of receptor regulation that were impossible in
mammalian cells. These studies showed the importance of
post-translational modifications and also led to the identi-
fication of cellular determinants responsible for those
modifications and their modulation. For example, differ-
ential agonist-induced phosphorylation of human kinin
receptors B1 and B2 [146] and human muscarinic m1
and m2 receptors [72] were observed. Similarly, identifi-
cation of the GRKs responsible for agonist-induced phos-
phorylation of the muscarinic m3 receptor was achieved by
addition of purified GRKs to the membrane-bound recep-
tor [73]. Also, substance P receptor phosphorylation was
shown to be mediated by GRK2 but distinctly regulated
by Ghg compared to rhodopsin or the h2-adrenergic
receptor [76]. Another example demonstrated that Gg12
phosphorylation increased A1 adenosine receptor coupling
to Gi1a, markedly inhibited type II adenylyl cyclase
activation, but did not affect its ability to activate phos-
pholipase C [147].
5. GPCR overexpression in stable Sf cell lines
Stable expression in Sf9 insect cells can be achieved
using the baculovirus ‘immediate-early’ promoters that are
recognised and used by insect cell RNA polymerases with-
out requiring any additional viral encoded proteins. During
the normal viral replication cycle, these promoters are the
first to be switched on following viral entry in the cell (see
Fig. 1). Immediate-early promoters have been widely used
to engineer cell lines with improved post-translational
processing (see above), but very few attempts have been
made to express membrane proteins under their control.
Only expression of the h2-adrenergic receptor as well as
the nicotinic acetylcholine receptor a-subunit have been
reported in Sf9 cells under the control of the immediate-early
promoter, IE1, isolated from the baculovirus A. californica
(AcIE1) [105,148]. h2-Adrenergic receptor expression
ranged from 24000 to 350000 receptors/cell [105] which is
well below the 12–17 pmol/mg corresponding to at least 106
receptors/cell reported for its expression with the baculovirus
system under the control of the polyhedrin promoter [149].
Recently, a nonlytic vector system was described that
employs the Orgyia pseudotsugata multicapsid nucleopoly-
hedrosis virus immediate-early 2 (OpIE2) promoter for con-
stitutive expression of proteins in insect cells [150,151]. In an
isogenic plasmid background, the OpIE2 promoter is 5- to
100-fold more active than the AcIE1 promoter in transiently
transformed Sf9 cells [150]. Recently, this promoter has been
successfully used for human mu opioid receptor production
[152]. The receptor was fused to the gp64 signal sequence
and was detected at the cell surface by confocal imaging.
Expression levels were about 11000–15000 receptors/cell,
which can be estimated at 250 pmol/l culture. This is about 15
times less than the 2–3 106 receptors/cell, corresponding to
3200–4700 pmol/l culture, obtained when the same construct
was expressed with the baculovirus system under the control
of the polyhedrin promoter [29].
Though significantly lower levels of expression were
obtained under the control of ‘immediate-early’ promoters
when compared to the very late polyhedrin promoter, stably
transfected insect Sf9 cells may represent a valuable alter-
native for GPCR large-scale expression. Indeed, stably
transformed insect cells not only grow to high density in
suspension and adapt easily to serum-free medium but they
do not require the production of large-scale high-titre viral
stocks and allow continuous culture in a biofermentor.
Moreover, compared to mammalian cells, insect cells are
considerably less expensive and time-consuming to grow in
large volumes and reach higher cell densities.
6. Concluding remarks
Over the years, the baculovirus–insect cell system has
proven extremely effective for the production of large
amounts of many GPCRs with properties comparable to
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those of their native counterparts. Insect cells are indeed able
to perform post-translational modifications crucial for GPCR
function such as palmitoylation and phosphorylation. Recep-
tors produced in insect cells constitute, therefore, an excellent
source of material for structural studies. The expression
yields obtained for some GPCRs are high enough to produce
the milligram quantities required for solid-state NMR or 3D-
crystallisation. However, for many GPCRs, expression levels
are still too low for such ambitious goals or would at least
require very large culture volumes. GPCR expression and
purification, on the other hand, have been improved, but
some parameters designed to optimise expression remain
elusive and do not always act in a predictable manner.
Nevertheless, a lot of information has been gathered on the
system that will definitely help future studies and efforts are
still made to develop new approaches and optimise current
procedures.
The other striking breakthrough emerging from the use of
the baculovirus–insect cell system concerns the functional
study of GPCRs. Because of the high expression levels that
can be reached, many characteristics of GPCRs including
palmitoylation and phosphorylation were uncovered that
were not observed in mammalian cells because heterologous
expression did not produce sufficient amounts of receptors. In
addition, the ability to select GPCR and G protein combina-
tions, whether by co-expression or by reconstitution with
purified elements, has allowed the detailed characterisation of
preferred interactions. Moreover, the baculovirus–insect cell
system has become a tool of choice for pharmacologists
because it allows the study of ligand specificities on isolated
receptor subtypes. The system also provides material suitable
for drug screening. This includes the search for inverse
agonists by allowing the easy detection of receptor constit-
utive activity as a result of the high expression levels achieved
both for the receptor and its cognate G protein partners.
Advantages of the baculovirus–insect cell system in-
clude its simplicity to set up in any laboratory, the fact that
it does not require extensive biosafety measures, and that
it benefits from over 15 years of experience and of well-
established protocols. As a consequence, it represents a
valuable tool for GPCR studies whether the ultimate goal
is to gain structural information or to better understand the
regulation of the first steps of the signalling cascade.
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